For Research Use Only. Not for human consumption, diagnostic, or therapeutic use.
BioPeptidyne — Insights

Protocol guides, deep-science
& compound research.

All compound content in one place — practical protocol guides, market updates, peer-reviewed mechanism deep-dives, and sourcing analysis. Covering 17 articles across 7 categories.

17 Articles published
7 Categories covered
2026 Content season
All Protocol Guides Comparisons Deep Science Market Trends Product Spotlights
GLP-1 COMPARE Sema · Tirze
Retatro
−28.7% Phase 3
Comparisons May 4, 2026
Semaglutide vs Tirzepatide vs Retatrutide 2026: The Definitive Comparison Guide
Three generations of GLP-1 peptides compared side by side — with TRIUMPH-4 Phase 3 data (Retatrutide −28.7%), a full comparison table, reconstitution difficulty analysis, and selection logic from a competitive athletics coach.
BioPeptidyne Technical Team · 10 min read 中文版 Read article
TRIPLE RECEPTOR Retatrutide
2026
−28.7% Phase 3
Deep Dive May 4, 2026
Retatrutide 2026: Triple-Receptor Science, TRIUMPH-4 Phase 3 Data & Research Protocol Guide
TRIUMPH-4 confirmed: 12mg −28.7% over 68 weeks. Beyond the weight number — six metabolic benefits including WOMAC joint pain 75.8%, hepatic fat reduction, cardiovascular lipids, and the unique Glucagon-driven basal metabolic rate effect that Sema and Tirze can't replicate.
BioPeptidyne Technical Team · 12 min read 中文版 Read article
POST GLP-1 Metabolic
Recovery
67% regained in 12 mo
Metabolic Recovery May 5, 2026
Post-GLP-1 Metabolic Recovery: 67% of Weight Loss Regained in 12 Months — How to Stay in the Other 33%
STEP 1 extension study confirmed: the average researcher regains 67% of weight lost within one year of stopping. A systematic guide covering Ghrelin rebound mechanics, 4–8 week tapering strategy, the muscle-first defense, competition-grade nutrition, and the BioPeptidyne data tracking alert system.
BioPeptidyne Technical Team · 14 min read 中文版 Read article
STACK BPC-157
+TB-500
RECOVERY 2026
Protocol Guides May 4, 2026
BPC-157 & TB-500 Stack Guide 2026: The Science Behind Sports Injury Recovery
When a single peptide isn't enough. Deep-dive into the complementary mechanisms of BPC-157 (local angiogenesis) and TB-500 (systemic cell migration), with cycle planning logic, PPL training adjustments, and 4 expert FAQs.
BioPeptidyne Technical Team · 10 min read 中文版 Read article
ANTI-AGING · BEAUTY GHK-Cu
Reverse Aging
4,000 GENES · -56% WRINKLES
Anti-Aging · Beauty May 5, 2026
GHK-Cu Anti-Aging & Beauty Guide: Rewinding 4,000 Genes Back to Youth
Your body hasn't forgotten how to repair itself — it's lost the signal. GHK-Cu declines 60% between age 20 and 60. Covers the 4,000-gene DNA reset, 67% ATP upgrade, 56% wrinkle reduction, 80% DHT blockade for hair loss, and the 12/4 cycling protocol that prevents receptor adaptation.
BioPeptidyne Technical Team · 14 min read 中文版 Read article
BIOREGENERATION GHK-Cu
Clinical Guide
4,000 GENES · 12/4 PROTOCOL
Bioregeneration May 5, 2026
GHK-Cu Clinical Practice Guide: LRP1 Signaling, 4,000 Genes & the 12/4 Cycle Protocol
GHK-Cu concentrations fall 60% between age 20 and 60. This guide maps the LRP1 4-step cascade, the three biological failures it resolves (ATP shortage, inflammation, insulin resistance), cross-organ applications across four systems, and the cycling protocol that prevents receptor downregulation.
BioPeptidyne Technical Team · 18 min read 中文版 Read article
GH AXIS HGH · CJC-1295
Ipamorelin · IGF-1
4-TIER FRAMEWORK
Deep Analysis May 5, 2026
HGH vs CJC-1295/Ipamorelin vs IGF-1: The 4-Tier GH Axis Intervention Framework
Pituitary ceiling, Somatostatin brake mechanics, pulsatile vs. continuous lipolysis efficiency, the gold-standard Mod GRF + Ipamorelin stack, and the 86–94% cross-tier suppression trap. Covers all four intervention tiers with three goal-driven protocol profiles.
BioPeptidyne Technical Team · 16 min read 中文版 Read article
COMPARISON BPC-157
vs TB-500
VASCULAR · CELLULAR
Comparisons May 6, 2026
BPC-157 vs TB-500: Mechanisms, Differences & When to Stack
They're both repair peptides — but they operate on entirely different biological axes. BPC-157 builds vascular infrastructure via VEGFR2 and FAK-Paxillin; TB-500 mobilizes cellular repair crews via actin regulation. Comparison table, tissue targeting guide, and injection protocol logic.
BioPeptidyne Technical Team · 13 min read Read article
WEIGHT LOSS 2026 King of
Peptides
−28.7% · FAT MOBILIZATION
Fat Loss Strategy May 6, 2026
The King of Peptides for Weight Loss 2026: Retatrutide, AOD9604 & the Complete Fat-Loss Stack
Retatrutide's triple-receptor mechanism delivers −28.7% body weight. But the real system goes deeper: AOD9604 unlocks adipocyte mobilization, SLU-PP-332 resets metabolic enzymes, and MOTS-c forces mitochondrial fat-burning. Three systems, one strategic stack.
BioPeptidyne Technical Team · 15 min read Read article
PROTOCOL 配製 GUIDE 2026
Protocol Guides May 4, 2026
Peptide Reconstitution Guide 2026: Dilution Math, Step-by-Step Protocol & Storage Rules
Written by a nursing research graduate with 10+ years of competitive athletics coaching. Covers equipment setup, the 3-step wall-flow technique, dosage conversion formulas, and expert storage rules for BPC-157, GHK-Cu, Semaglutide and more.
BioPeptidyne Technical Team · 8 min read 中文版 Read article
Deep Science
Peer-reviewed mechanism reviews with PubMed citations — formerly the Research Library.
REPAIR · ANGIOGENESIS BPC-157
Master Regulator
VEGF · FAK-PAXILLIN · GI
Deep Science Apr 26, 2026
BPC-157: The Master Regulator of Systemic Repair
Comprehensive mechanism review covering VEGF/VEGFR2 angiogenesis, FAK-paxillin tendon remodelling, gastrointestinal cytoprotection, and NO system modulation — with 15 PubMed citations from the Sikiric laboratory series.
BioPeptidyne Research Team · 13 min read Read article
GENOMICS · LONGEVITY GHK-Cu
Genomic Reset
4,000 GENES · SP1 AXIS
Deep Science Apr 26, 2026
GHK-Cu: Genomic Modulation and Rejuvenation Science
How a single copper tripeptide resets over 4,000 aging-associated genes via Sp1 transcription factor binding. Covers LRP1 receptor cascade, collagen ECM rebuilding, Wnt/β-catenin hair follicle activation, and DHT pathway inhibition.
BioPeptidyne Research Team · 14 min read Read article
TISSUE ENGINEERING GHK-Cu
Regenerative
WOUND · SCAFFOLD · ECM
Deep Science Apr 26, 2026
GHK-Cu: Regenerative Potential in Tissue Engineering
From wound-healing scaffolds to hair follicle bioreactors — how GHK-Cu integrates into biomaterial matrices to accelerate tissue regeneration. Covers ECM remodelling enzymes, MMP regulation, and clinical wound healing data.
BioPeptidyne Research Team · 12 min read Read article
GLP-1 PHARMACOLOGY Semaglutide
Ozempic / Wegovy
−15.3% STEP 1 · RECEPTOR
Deep Science May 4, 2026
Semaglutide (Ozempic · Wegovy): GLP-1 Receptor Pharmacology & Clinical Weight Loss Data
The pharmacokinetics behind once-weekly dosing: fatty acid albumin binding, GLP-1 receptor signalling cascade, central and peripheral appetite suppression, STEP 1–8 trial data, and mechanistic comparison against tirzepatide and retatrutide.
BioPeptidyne Research Team · 12 min read Read article
DUAL RECEPTOR Tirzepatide
Mounjaro
GIP + GLP-1 · SURMOUNT
Deep Science May 4, 2026
Tirzepatide (Mounjaro · Zepbound): Dual GIP+GLP-1 Receptor Pharmacology & SURMOUNT Data
Why dual-receptor agonism outperforms single GLP-1 targeting: GIP receptor's role in adipose lipid uptake, the synergistic insulin secretion mechanism, SURMOUNT-1 −22.5% data, and the pharmacokinetic half-life profile enabling weekly dosing.
BioPeptidyne Research Team · 13 min read Read article
TRIPLE RECEPTOR Retatrutide
Phase 2 Science
GLP-1 · GIP · GCG
Deep Science May 4, 2026
Retatrutide: Triple GLP-1/GIP/Glucagon Receptor Agonism & Phase 2 Weight Loss Data
The first compound to simultaneously engage all three incretin/glucagon receptors: mechanistic breakdown of GCG receptor-driven BMR elevation, Phase 2 −24.2% data at 48 weeks, and the pharmacological basis for superior adipose tissue lipolysis.
BioPeptidyne Research Team · 14 min read Read article
LONGEVITY · SIRTUINS NAD+
Longevity
SIRT1-7 · NMN · AGING
Deep Science May 4, 2026
NAD+ and Aging: Cellular Energy Decline, Sirtuin Activation & NMN Research
NAD+ declines ~50% from age 20 to 70, directly impairing SIRT1-7 deacetylase activity and PARP-mediated DNA repair. Deep-dive into the salvage pathway, NMN vs NR precursor comparison, and the case for IV/IM delivery in rapid intracellular repletion models.
BioPeptidyne Research Team · 11 min read Read article
Upcoming topics
⚗️
Protocol Guides
Reconstitution · Dosing · Storage
📊
Market Trends
GLP-1 · Longevity · 2026
🔍
Compound Comparisons
Sema vs Tirze vs Retatro
Product Spotlights
New catalog additions
📦
Sourcing & Quality
HPLC · CoA · Purity